

DAFTAR PUSTAKA

- Abou-Ismaïl, M.Y., Diamond, A., Kapoor, S., Arafah, Y., dan Nayak, L., 2020. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. *Thrombosis Research*, **194**: 101–115.
- Ahmed, I., Majeed, A., dan Powell, R., 2007. Heparin induced thrombocytopenia: diagnosis and management update. *Postgraduate Medical Journal*, **83**: 575–582.
- Albani, F., Sepe, L., Fusina, F., Prezioso, C., Baronio, M., Caminiti, F., dkk., 2020. Thromboprophylaxis with enoxaparin is associated with a lower death rate in patients hospitalized with SARS-CoV-2 infection. A cohort study. *EClinicalMedicine*, **27**: 100562.
- Alqubanchi, F.B. dan Al-Hamadani, F.Y., 2021. A Pharmacoeconomics Study for Anticoagulants used for Hospitalized COVID-19 Patients in Al-Najaf Al-Ashraf city –Iraq(Conference Paper)#. *Iraqi Journal of Pharmaceutical Sciences (IJPS)*, **30**: 48–59.
- Araya, S., Mamo, M.A., Tsegay, Y.G., Atlaw, A., Aytenew, A., Hordofa, A., dkk., 2021. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. *PloS One*, **16**: e0252939.
- Arepally, G.M., 2017. Heparin-induced thrombocytopenia. *Blood*, **129**: 2864–2872.
- Arslan, Y., Yilmaz, G., Dogan, D., Hasirci, M., Cetindogan, H., Ocal, N., dkk., 2021. The effectiveness of early anticoagulant treatment in Covid-19 patients. *Phlebology*, **36**: 384–391.
- Assinger, A., 2014. Platelets and infection - an emerging role of platelets in viral infection. *Frontiers in Immunology*, **5**: 649.
- ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P.R., Goligher, E.C., Berger, J.S., dkk., 2021. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *The New England Journal of Medicine*, **385**: 790–802.
- Barnes, G.D., Burnett, A., Allen, A., Blumenstein, M., Clark, N.P., Cuker, A., dkk., 2020. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *Journal of Thrombosis and Thrombolysis*, **50**: 72–81.
- Biancolella, M., Colona, V.L., Mehrian-Shai, R., Watt, J.L., Luzzatto, L., Novelli, G., dkk., 2022. COVID-19 2022 update: transition of the pandemic to the endemic phase. *Human Genomics*, **16**: 19.
- Bilaloglu, S., Aphinyanaphongs, Y., Jones, S., Iturrate, E., Hochman, J., dan Berger, J.S., 2020. Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System. *JAMA*, **324**: 799–801.
- Billett, H.H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R., Lo, Y., dkk., 2020. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thrombosis and Haemostasis*, **120**: 1691–1699.
- Buryachkovskaya, L., Lomakin, N., Melkumyants, A., Docenko, J., Ermishkin, V., dan Serebruany, V., 2021. Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study. *Reviews in Cardiovascular Medicine*, **22**: 1685–1691.
- Cannegieter, S.C. dan Klok, F.A., 2020. COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. *Research and Practice in Thrombosis and Haemostasis*, **4**: 439–445.

- Capodanno, D. dan Angiolillo, D.J., 2012. Antithrombotic therapy in patients with chronic kidney disease. *Circulation*, **125**: 2649–2661.
- Cardillo, G., Viggiano, G.V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., dkk., 2021. Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. *Journal of Blood Medicine*, **12**: 69–75.
- Chan, J.F.-W., Yuan, S., Kok, K.-H., To, K.K.-W., Chu, H., Yang, J., dkk., 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet (London, England)*, **395**: 514–523.
- Chiappelli, F., Khakshooy, A., dan Greenberg, G., 2020. CoViD-19 Immunopathology and Immunotherapy. *Bioinformation*, **16**: 219–222.
- Crooks, J. dan Stevenson, I.H., 1981. Drug response in the elderly--sensitivity and pharmacokinetic considerations. *Age and Ageing*, **10**: 73–80.
- Cui, S., Chen, S., Li, X., Liu, S., dan Wang, F., 2020. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. *Journal of Thrombosis and Haemostasis*, 10.1111/jth.14830.
- Cuker A, Tseng EK, Nieuwlaat R, dkk., 2020. 'ASH Guidelines on Use of Anticoagulation in Patients with COVID-19 - Hematology.org', . URL: <https://www.hematology.org:443/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/ash-guidelines-on-use-of-anticoagulation-in-patients-with-covid-19> (diakses tanggal 13/11/2021).
- de Wit, E., van Doremalen, N., Falzarano, D., dan Munster, V.J., 2016. SARS and MERS: recent insights into emerging coronaviruses. *Nature Reviews. Microbiology*, **14**: 523–534.
- Duployez, C., Le Guern, R., Tinez, C., Lejeune, A.-L., Robriquet, L., Six, S., dkk., 2020. Panton-Valentine Leukocidin-Secreting Staphylococcus aureus Pneumonia Complicating COVID-19. *Emerging Infectious Diseases*, **26**: 1939–1941.
- Esmon, C.T., 2005. The interactions between inflammation and coagulation. *British Journal of Haematology*, **131**: 417–430.
- Fehr, A.R. dan Perlman, S., 2015. Coronaviruses: an overview of their replication and pathogenesis. *Methods in Molecular Biology (Clifton, N.J.)*, **1282**: 1–23.
- Fox, S.E., Akmatbekov, A., Harbert, J.L., Li, G., Quincy Brown, J., dan Vander Heide, R.S., 2020. Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *The Lancet. Respiratory Medicine*, **8**: 681–686.
- Gandhi, R.T., Lynch, J.B., dan del Rio, C., 2020. Mild or Moderate Covid-19. *New England Journal of Medicine*, **383**: 1757–1766.
- Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., dkk., 2020. 'Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation', , *preprint*, . Infectious Diseases (except HIV/AIDS).
- Gauer, R.L. dan Braun, M.M., 2012. Thrombocytopenia. *American Family Physician*, **85**: 612–622.
- Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R., dkk., 2008. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, **133**: 381S–453S.

- Gholami, K. dan Shalviri, G., 1999. Factors associated with preventability, predictability, and severity of adverse drug reactions. *The Annals of Pharmacotherapy*, **33**: 236–240.
- Giannis, D., Ziogas, I.A., dan Gianni, P., 2020. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology*, **127**: 104362.
- Gormez, S., Gumusel, H.K., Ekicibasi, E., Degirmencioglu, A., Paudel, A., Akan, G., dkk., 2021. Impact of proactive low-molecular weight heparin therapy on outcomes in COVID-1. *Bratislavske Lekarske Listy*, **122**: 582–589.
- Gresham, C., Levine, M., dan Ruha, A.-M., 2009. Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose. *Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology*, **5**: 242–249.
- Hajra, A., Mathai, S.V., Ball, S., Bandyopadhyay, D., Veyseh, M., Chakraborty, S., dkk., 2020. Management of Thrombotic Complications in COVID-19: An Update. *Drugs*, **80**: 1553–1562.
- Han, M., Yan, W., Huang, Y., Yao, H., Wang, Z., Xi, D., dkk., 2008. The nucleocapsid protein of SARS-CoV induces transcription of hfgl2 prothrombinase gene dependent on C/EBP alpha. *Journal of Biochemistry*, **144**: 51–62.
- Harter, K., Levine, M., dan Henderson, S.O., 2015. Anticoagulation Drug Therapy: A Review. *Western Journal of Emergency Medicine*, **16**: 11–17.
- Hayiroğlu, M.İ., Çınar, T., dan Tekkeşin, A.İ., 2020. Fibrinogen and D-dimer variances and anticoagulation recommendations in Covid-19: current literature review. *Revista Da Associacao Medica Brasileira (1992)*, **66**: 842–848.
- Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., dkk., 2020. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive Care Medicine*, **46**: 1089–1098.
- Henry, B.M., de Oliveira, M.H.S., Benoit, S., Plebani, M., dan Lippi, G., 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clinical Chemistry and Laboratory Medicine*, **58**: 1021–1028.
- Hilmer, S.N., McLachlan, A.J., dan Le Couteur, D.G., 2007. Clinical pharmacology in the geriatric patient. *Fundamental & Clinical Pharmacology*, **21**: 217–230.
- Hottz, E.D., Azevedo-Quintanilha, I.G., Palhinha, L., Teixeira, L., Barreto, E.A., Pão, C.R.R., dkk., 2020. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood*, **136**: 1330–1341.
- Hughes, S., Szeki, I., Nash, M.J., dan Thachil, J., 2014. Anticoagulation in chronic kidney disease patients-the practical aspects. *Clinical Kidney Journal*, **7**: 442–449.
- Hunt B, Retter A, McClintock C, 2020. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19.
- Ikatan Dokter Indonesia, 2020. Rekomendasi IDI Pemberian Antikoagulan Profilaksis pada Pasien COVID-19 yang Dirawat di Rumah Sakit.
- Inui, S., Fujikawa, A., Jitsu, M., Kunishima, N., Watanabe, S., Suzuki, Y., dkk., 2020. Chest CT Findings in Cases from the Cruise Ship Diamond Princess with Coronavirus Disease (COVID-19). *Radiology: Cardiothoracic Imaging*, **2**: e200110.

- Ionescu, F., Jaiyesimi, I., Petrescu, I., Lawler, P.R., Castillo, E., Munoz-Maldonado, Y., dkk., 2021. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. *European Journal of Haematology*, **106**: 165–174.
- Jiang, L., Li, Y., Du, H., Qin, Z., dan Su, B., 2021. Effect of Anticoagulant Administration on the Mortality of Hospitalized Patients With COVID-19: An Updated Systematic Review and Meta-Analysis. *Frontiers in Medicine*, **8**: 698935.
- Jin, Y., Yang, H., Ji, W., Wu, W., Chen, S., Zhang, W., dkk., 2020. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. *Viruses*, **12**: 372.
- Joly, B.S., Siguret, V., dan Veyradier, A., 2020. Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. *Intensive Care Medicine*, **46**: 1603–1606.
- Khizroeva, J.H., Makatsariya, A.D., Bitsadze, V.O., Tretyakova, M.V., Slukhanchuk, E.V., Elalamy, I., dkk., 2020. Laboratory monitoring of COVID-19 patients and importance of coagulopathy markers. *Obstetrics, Gynecology and Reproduction*, **14**: 132–147.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., dkk., 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*, **191**: 145–147.
- Kluge, S., Janssens, U., Welte, T., Weber-Carstens, S., Marx, G., dan Karagiannidis, C., 2020. German recommendations for critically ill patients with COVID-19. *Medizinische Klinik - Intensivmedizin und Notfallmedizin*, **115**: 111–114.
- Kolanko, E., Senderek, T., Prokop-Staszecka, A., Kruk, A., Broniatowska, E., Koniecznyńska, M., dkk., 2021. Thromboprophylaxis in hospitalized COVID-19 patients: the efficacy and safety of the approved hospital protocol. *Polish Archives of Internal Medicine*, **131**: 16102.
- Kubitza, D., Becka, M., Roth, A., dan Mueck, W., 2008. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. *Current Medical Research and Opinion*, **24**: 2757–2765.
- Lemos, A.C.B., do Espírito Santo, D.A., Salvetti, M.C., Gilio, R.N., Agra, L.B., Pazin-Filho, A., dkk., 2020. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thrombosis Research*, **196**: 359–366.
- Levi, M. dan Poll, T. van der, 2015. Coagulation in patients with severe sepsis. *Seminars in Thrombosis and Hemostasis*, **41**: 9–15.
- Li, J., Liu, Z., Wu, G., Yi, M., Chen, Y., Li, K., dkk., 2020. D-Dimer as a Prognostic Indicator in Critically Ill Patients Hospitalized With COVID-19 in Leishenshan Hospital, Wuhan, China. *Frontiers in Pharmacology*, **11**: 600592.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., dkk., 2020. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *The New England Journal of Medicine*, **382**: 1199–1207.
- Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A., dkk., 2003. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature*, **426**: 450–454.
- Lim, W., Meade, M., Lauzier, F., Zarychanski, R., Mehta, S., Lamontagne, F., dkk., 2015. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*. *Critical Care Medicine*, **43**: 401–410.

- Liu, B., Li, M., Zhou, Z., Guan, X., dan Xiang, Y., 2020. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? *Journal of Autoimmunity*, **111**: 102452.
- Lodigiani, C., Iapichino, G., Carenzo, L., Cecconi, M., Ferrazzi, P., Sebastian, T., dkk., 2020. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis Research*, **191**: 9–14.
- Lopes, R.D., de Barros E Silva, P.G.M., Furtado, R.H.M., Macedo, A.V.S., Bronhara, B., Damiani, L.P., dkk., 2021. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet (London, England)*, **397**: 2253–2263.
- Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., dkk., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet*, **395**: 565–574.
- Luo, H.-C., You, C.-Y., Lu, S.-W., dan Fu, Y.-Q., 2021. Characteristics of coagulation alteration in patients with COVID-19. *Annals of Hematology*, **100**: 45–52.
- Ma, L., Song, K., dan Huang, Y., 2021. Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. *Journal of Cardiothoracic and Vascular Anesthesia*, **35**: 1860–1865.
- Madoiwa, S., 2015. Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC. *Journal of Intensive Care*, **3**: 8.
- Marchandot, B., Sattler, L., Jesel, L., Matsushita, K., Schini-Kerth, V., Grunebaum, L., dkk., 2020. COVID-19 Related Coagulopathy: A Distinct Entity? *Journal of Clinical Medicine*, **9**: 1651.
- Mattioli, M., Benfaremo, D., Mancini, M., Mucci, L., Mainquà, P., Polenta, A., dkk., 2021. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. *Journal of Thrombosis and Thrombolysis*, **51**: 286–292.
- Mennuni, M.G., Renda, G., Grisafi, L., Rognoni, A., Colombo, C., Lio, V., dkk., 2021. Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. *Journal of Thrombosis and Thrombolysis*, **52**: 782–790.
- Merad, M. dan Martin, J.C., 2020. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nature Reviews. Immunology*, **20**: 355–362.
- Musoke, N., Lo, K.B., Albano, J., Peterson, E., Bhargav, R., Gul, F., dkk., 2020. Anticoagulation and bleeding risk in patients with COVID-19. *Thrombosis Research*, **196**: 227–230.
- Ng, L.F.P., Hibberd, M.L., Ooi, E.-E., Tang, K.-F., Neo, S.-Y., Tan, J., dkk., 2004. A human in vitro model system for investigating genome-wide host responses to SARS coronavirus infection. *BMC infectious diseases*, **4**: 34.
- Nugroho, J., Wardhana, A., Mulia, E.P., Maghfirah, I., Rachmi, D.A., A'yun, M.Q., dkk., 2021. Elevated fibrinogen and fibrin degradation product are associated with poor outcome in COVID-19 patients: A meta-analysis. *Clinical Hemorheology and Microcirculation*, **77**: 221–231.
- Oudkerk, M., Büller, H.R., Kuijpers, D., van Es, N., Oudkerk, S.F., McLoud, T., dkk., 2020. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. *Radiology*, **297**: E216–E222.

- 'Our World in Data', 2022. *Our World in Data*. URL: <https://ourworldindata.org> (diakses tanggal 2/7/2022).
- Pangarsa, E.A., Setiawan, B., Santosa, D., Naibaho, R.M., Rizky, D., -, S., dkk., 2020. Position paper from the Indonesian Society of Thrombosis and Hemostasis (InaSTH), Semarang chapter: Management of coagulopathy in COVID-19. *Bali Medical Journal*, **9**: 482.
- Paolisso, P., Bergamaschi, L., D'Angelo, E.C., Donati, F., Giannella, M., Tedeschi, S., dkk., 2020. Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. *Frontiers in Pharmacology*, **11**: 1124.
- Pavoni, V., Ganesello, L., Pazzi, M., Stera, C., Meconi, T., dan Frigieri, F.C., 2020. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action. *Thrombosis Research*, **196**: 313–317.
- Perepu, U.S., Chambers, I., Wahab, A., Ten Eyck, P., Wu, C., Dayal, S., dkk., 2021. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. *Journal of thrombosis and haemostasis: JTH*, **19**: 2225–2234.
- Pesavento, R., Ceccato, D., Paschetto, G., Monticelli, J., Leone, L., Frigo, A., dkk., 2020. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. *Journal of Thrombosis and Haemostasis*, 10.1111/jth.15022.
- Previtali, E., Bucciarelli, P., Passamonti, S.M., dan Martinelli, I., 2011. Risk factors for venous and arterial thrombosis. *Blood Transfusion = Trasfusione Del Sangue*, **9**: 120–138.
- Promislow, D.E.L., 2020. A Geroscience Perspective on COVID-19 Mortality. *The Journals of Gerontology: Series A*, **75**: e30–e33.
- REMAP-CAP Investigators, ACTIV-4a Investigators, ATTACC Investigators, Goligher, E.C., Bradbury, C.A., McVerry, B.J., dkk., 2021. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *The New England Journal of Medicine*, **385**: 777–789.
- Revicki, D.A. dan Frank, L., 1999. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. *Pharmacoeconomics*, **15**: 423–434.
- Sadeghipour, P., Talasaz, A.H., Rashidi, F., Sharif-Kashani, B., Beigmohammadi, M.T., Farokhpour, M., dkk., 2021. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit. *JAMA*, **325**: 1–11.
- Senst, B., Tadi, P., Goyal, A., dan Jan, A., 2021. Hypercoagulability, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).
- Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., dkk., 2020. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. *Clinical and Translational Science*, **13**: 1087–1095.
- Sholzberg, M., Tang, G.H., Rahhal, H., AlHamzah, M., Kreuziger, L.B., Áinle, F.N., dkk., 2021. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. *The BMJ*, **375**: n2400.
- Sunggoro, A.J., Purwanto, I., dan Hasan, M., 2020. Trombosis pada corona virus disease (COVID-19). *Jurnal Kedokteran Syiah Kuala*, **20**: .

- Tang, N., Li, D., Wang, X., dan Sun, Z., 2020. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of thrombosis and haemostasis: JTH*, **18**: 844–847.
- Terpos, E., Ntanasios-Stathopoulos, I., Elalamy, I., Kastritis, E., Sergentanis, T.N., Politou, M., dkk., 2020. Hematological findings and complications of COVID-19. *American Journal of Hematology*, **95**: 834–847.
- Thachil, J., Tang, N., Gando, S., Falanga, A., Cattaneo, M., Levi, M., dkk., 2020. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. *Journal of thrombosis and haemostasis: JTH*, **18**: 1023–1026.
- Trinh, M.A., Chang, D.R., Govindarajulu, U.S., Kane, E., Fuster, V., Kohli-Seth, R., dkk., 2020. Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients.
- Ugur, M., Adiyek, E., Recep, E., Bakan, N., dan Yiyit, N., 2021. Aggressive Thromboprophylaxis Improves Clinical Process and Decreases the Need of Intensive Care Unit in Covid-19. *Pakistan Journal of Medical Sciences*, **37**: 668–674.
- Ullah, W., Saeed, R., Sarwar, U., Patel, R., dan Fischman, D.L., 2020. COVID-19 Complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure. *JACC: Case Reports*, **2**: 1379–1382.
- Varga, Z., Flammer, A.J., Steiger, P., Haberecker, M., Andermatt, R., Zinkernagel, A.S., dkk., 2020. Endothelial cell infection and endotheliitis in COVID-19. *Lancet (London, England)*, **395**: 1417–1418.
- Website Resmi Penanganan, C.-19, 2022. 'Situasi COVID-19 di Indonesia (Update per 20 Juni 2022)', *covid19.go.id*. URL: <https://covid19.go.id/artikel/2022/06/20/situasi-covid-19-di-indonesia-update-20-juni-2022> (diakses tanggal 5/7/2022).
- Wells, B.G., DiPiro, Joseph T, Schwinghammer, Terry L, dan DiPiro, Cecily V, 2015. *Pharmacotherapy Handbook*.
- Wells, G.A., Elliott, J., Kelly, S., Bai, Z., Boucher, M., Skidmore, B., dkk., 2019. *Bleeding Classification System Definitions*, Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: Clinical and Economic Impact of Standard Versus Extended Duration [Internet]. Canadian Agency for Drugs and Technologies in Health.
- WHO, 2020. 'Coronavirus disease (COVID-19)', . URL: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019> (diakses tanggal 10/10/2021).
- WHO, 2021. 'Situation reports', . URL: <https://www.who.int/indonesia/news/novel-coronavirus/situation-reports> (diakses tanggal 20/12/2021).
- Witkowski, M., Landmesser, U., dan Rauch, U., 2016. Tissue factor as a link between inflammation and coagulation. *Trends in Cardiovascular Medicine*, **26**: 297–303.
- Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, Xing, Xu, S., dkk., 2020. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA internal medicine*, **180**: 934–943.
- Xu, R., Zhou, Y., Cai, L., Wang, L., Han, J., Yang, X., dkk., 2020. Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19. *The British Journal of Dermatology*, **183**: 1145–1147.
- Yang, X., Yang, Q., Wang, Y., Wu, Y., Xu, J., Yu, Y., dkk., 2020. Thrombocytopenia and its association with mortality in patients with COVID-19. *Journal of thrombosis and haemostasis: JTH*, **18**: 1469–1472.

- Yorike, D., Kurniawan, M.R., dan Syafaat, M., 2022. Analysis of D-Dimer Level and Prothombin Time (PT) Activated Prothombin Thromboplastin (APTT) on Heparin Administration to COVID-19 Patients. *Indonesian Journal of Medical Laboratory Science and Technology*, **4**: 91–98.
- YORMAZ, B., ERGÜN, D., TÜLEK, B., ERGÜN, R., ARSLAN, U., dan KANAT, F., 2021. Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease. *Turkish Journal of Medical Sciences*, **51**: 28–38.
- Zaim, S., Chong, J.H., Sankaranarayanan, V., dan Harky, A., 2020. COVID-19 and Multiorgan Response. *Current Problems in Cardiology*, **45**: 100618.
- Zhang, R., Ouyang, H., Fu, L., Wang, S., Han, J., Huang, K., dkk., 2020. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. *European Radiology*, **30**: 4417–4426.
- Zhang, X., Kimura, Y., Fang, C., Zhou, L., Sfyroera, G., Lambris, J.D., dkk., 2007. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. *Blood*, **110**: 228–236.
- Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., dkk., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England)*, **395**: 1054–1062.
- Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., dkk., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, **579**: 270–273.
- Zumla, A., Hui, D.S., Azhar, E.I., Memish, Z.A., dan Maeurer, M., 2020. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *Lancet (London, England)*, **395**: e35–e36.